Promising Activity of Patritumab Deruxtecan in Patients with HR-positive, HER2-negative MBC Who Progressed on CDK4/6 Inhibitors By Ogkologos - September 23, 2025 296 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ICARUS-BREAST01 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR What Is a Living Will and Why Should You Create One... May 11, 2023 Efficacy of Sunitinib in Patients with Metastatic Phaeochromocytomas and Paragangliomas March 12, 2024 Reunión anual de la American Society of Clinical Oncology de 2021:... June 3, 2021 Pirtobrutinib Shows Efficacy in Patients with Heavily Pretreated CLL or SLL... July 18, 2023 Load more HOT NEWS Does Too Much Fructose Help Colorectal Cancers Grow? Molecular Determinants of Sotorasib Efficacy in Patients with Advanced KRASG12C-mutated NSCLC Cómo encontrar la fuerza interior me ayudó a recuperarme del cáncer Osimertinib Shows Promising Activity in Previously Untreated Patients with Metastatic NSCLC...
